Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

Publication date: May 31, 2025

Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE. Participants received either a 10 g dose of mRNA-1283 or a 50 g dose of mRNA-1273. Ask your healthcare provider about any side effects that concern you. COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone.

Concepts Keywords
Breastfeedinghave Allergic
Facebook Covid
Fda Dose
Weaknessmyocarditis Looking
Mnexspike
Moderna
Modernas
Mrna
Older
Received
Severe
Statements
Vaccine
Vaccines
Years

Semantics

Type Source Name
pathway REACTOME Release
disease IDO blood
disease MESH bleeding
disease MESH pain joint
disease MESH Injection site reactions
disease MESH Myocarditis
disease MESH pericarditis
disease MESH inflammation
disease MESH allergic reaction
drug DRUGBANK Coenzyme M
disease MESH rare diseases
disease MESH autoimmune diseases
drug DRUGBANK Nonoxynol-9
disease MESH COVID-19
disease IDO site
disease MESH infectious diseases

Original Article

(Visited 1 times, 1 visits today)